Pembrolizumab (Keytruda): Competitive Landscape and What CI Teams Should Watch

Pembrolizumab, marketed as Keytruda, is a PD-1 immune checkpoint inhibitor and one of the most widely used cancer drugs in the world. Its breadth is the reason it dominates competitive intelligence conversations: a shift in one tumor type can ripple across many.

Mechanism at a glance

Pembrolizumab is a humanized IgG4 monoclonal antibody that binds PD-1 on T cells, preventing PD-L1 and PD-L2 on tumor cells from switching them off. It is given by intravenous infusion or, since September 2025 in the US, as a subcutaneous injection (Keytruda Qlex), and immune-related adverse events such as colitis, pneumonitis, thyroid disorders and hepatitis are the characteristic safety considerations.

Why it matters

Pembrolizumab’s first approvals came in melanoma in 2014, and its labels have since expanded across lung, head and neck, bladder, kidney, gastric, cervical, endometrial, triple-negative breast and other cancers, in monotherapy and in combination with chemotherapy or targeted agents. It also carries a tissue-agnostic indication for biomarker-defined tumors. For many sponsors, “plus pembrolizumab” has become the default backbone of a combination trial.

Competitive pressure points

• Other PD-(L)1 agents: nivolumab, atezolizumab, durvalumab, cemiplimab and others compete setting by setting.
• Next-generation bispecifics: antibodies that combine PD-1 blockade with VEGF or other targets aim to beat the established class in head-to-head trials.
• Formulations: a subcutaneous version, Keytruda Qlex, was approved by the FDA in September 2025 and by the European Commission in November 2025, giving the franchise a lifecycle strategy.
• Loss of exclusivity: Merck has pointed to 2028, and biosimilar developers are already filing in some markets.

What to watch

1. Phase 3 readouts of PD-1/VEGF bispecifics against pembrolizumab-based regimens.
2. Perioperative and early-stage expansions, where treatment duration and cost are debated.
3. Biomarker refinement, such as PD-L1 thresholds, that can shrink or grow addressable populations.
4. Biosimilar filings and the pricing response.

For related context, see our guides to oncology pipeline tracking and treatment algorithm maps.

Recent developments

Updated October 8, 2026. Items are drawn from company announcements, regulators and trade press; links go to the sources.

• Aug 10, 2026: Samsung Bioepis filed SB27, a pembrolizumab biosimilar, with Korea’s MFDS. Its Phase 3 is expected to conclude by the end of 2026. (PearceIP)
• Aug 2026: Merck reported Q2 sales of $8.37 billion for Keytruda and Keytruda Qlex (up 5%), including $463 million for Qlex, and a goal of 30-40% subcutaneous adoption by the end of 2027. Its CEO called the 2028 loss of exclusivity “more of a hill than a cliff.” (Reuters via BNN Bloomberg)
• Jul 23, 2026: Summit reported that the FDA accepted its ivonescimab application (EGFR-mutated non-squamous NSCLC after TKI therapy, based on HARMONi) with a PDUFA date of November 14, 2026. That filing is not a head-to-head comparison with pembrolizumab. (Summit Q2 report)
• Jul 2026: FDA approved Keytruda or Keytruda Qlex with Padcev before and after cystectomy for muscle-invasive bladder cancer regardless of cisplatin eligibility (KEYNOTE-B15/EV-304). Merck reports a 47% reduction in the risk of an event-free survival event (HR 0.53). Merck announced it July 10; some outlets date it July 11. (RTTNews)
• Jun 2026: FDA approved Keytruda or Keytruda Qlex with Welireg (belzutifan) as adjuvant treatment of intermediate-high or high-risk clear cell renal cell carcinoma on June 12 (LITESPARK-022, 28% reduction in risk of recurrence, metastasis or death). On June 24 it approved Trodelvy with Keytruda for first-line PD-L1-positive triple-negative breast cancer (ASCENT-04: median PFS 11.2 vs 7.8 months). (CURE)
• May 30, 2026: At ASCO, BioNTech and BMS reported Phase 2 data for pumitamig (a PD-L1/VEGF bispecific) in first-line NSCLC: confirmed response rates of 57.1% (non-squamous) and 68.4% (squamous) in 40 evaluable patients. Phase 3 trials against pembrolizumab regimens are under way. (BioNTech 6-K)
• Apr 30, 2026: Summit disclosed that an interim PFS analysis in the squamous cohort of HARMONi-3 (ivonescimab plus chemotherapy vs pembrolizumab plus chemotherapy, first-line NSCLC) did not reach its predefined threshold. The trial continues blinded, with the final squamous analysis expected in the second half of 2026. (ApexOnco)
• Nov 19, 2025: The European Commission approved subcutaneous Keytruda for all 33 adult indications approved in the EU. (Merck)
• Sep 19, 2025: FDA approved Keytruda Qlex (pembrolizumab with berahyaluronidase alfa) for the solid-tumor indications of IV pembrolizumab. In the pivotal study, the response rate was 45% subcutaneous vs 42% IV (n=377, NSCLC). (FDA)

Upcoming catalysts

• Oct 23-27, 2026: ESMO Congress, Madrid.
• Nov 14, 2026: FDA action date for Summit’s ivonescimab application.
• Second half of 2026: final squamous PFS analysis of HARMONi-3; the non-squamous analysis is expected in the first half of 2027.
• By end of 2026: Samsung Bioepis expects its SB27 Phase 3 to conclude.

Bottom line

Pembrolizumab remains the incumbent to beat. For competitors the question is no longer whether checkpoint inhibition works, but whether a new mechanism, format or combination can show a clear advantage over it in randomized trials.

Want this kind of analysis for the cancer areas you compete in? Request information and we will share sample deliverables.

This article is for informational and competitive-intelligence purposes only and is not medical advice. Approvals, labels and trial results change; verify details against current prescribing information and primary sources.